Revvity EBIT

The latest EBIT for RVTY is $360M as of March 2026. That compares with $450M in the prior-year period — down 19.6% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Revvity's historical trend and sector peers before judging valuation or financial health.

Over the past year, RVTY's EBIT moved from $450M to $360M — a 19.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Revvity's operating scale or balance-sheet position.

Against Healthcare companies, RVTY currently prints $360M for EBIT, while the sector average sits near $23B. That is roughly 98.5% below the sector mean. Large gaps often invite a closer look at Revvity's growth, margins, and balance sheet.

A EBIT figure of $360M for RVTY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting RVTY's EBIT ($360M), review year-over-year change from $450M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.